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iv 
Abstract 
 
 
The goal of this study is to develop small molecule inhibitors of DHPS for the 
treatment of a variety of infectious diseases. According to the World Health Organization 
(WHO), infectious diseases kill more than 13 million people worldwide every year 
making it the second leading cause of death behind cardiovascular disease. The 
sulfonamide class of drugs has been in use since the 1930’s to treat many infectious 
agents and act by targeting the enzyme dihydropteroate synthase (DHPS) of the 
prokaryotic and lower eukaryotic folate pathway.  
 
DHPS is an ideal drug target because humans do not synthesize folate de novo 
and is a well validated system. However, the emergence of bacterial resistance has 
limited the efficacy of sulfonamides, and an increasing trend in drug resistance has 
heightened the need for development of new therapeutics. Although drug resistance has 
severely limited the clinical use of sulfonamides, the folate pathway, and DHPS in 
particular, remain an ideal target for therapeutic development. This is due to the fact that 
DHPS accommodates two substrates, para-aminobenzoic acid (pABA) and 6-
hydroxymethyl-7,8-dihydropterin-pyrophosphate (DHPPP), which bind to separate and 
distinct regions of the protein. Sulfonamides act by binding the pABA pocket composed 
largely of dynamic loop regions which fold in upon substrate binding to complete the 
active site. In contrast, the pterin pocket is a highly conserved, rigid binding site, and is 
predicted to be more suitable for the development of small molecule inhibitors. 
Therefore, we propose targeting the pterin binding site as a means of developing novel 
small molecule inhibitors of DHPS.  
 
The advantages of this method are that pterin binds to a distinct region of DHPS 
separate from the pABA binding site and removed from areas known to accommodate 
sulfonamide resistance. In addition, it provides a novel approach to exploit a well 
validated drug target. We hypothesize that pterin-based compounds will provide a new 
class of antibiotics that will overcome the problems of drug resistance and provide novel 
therapeutics for a broad spectrum of infectious diseases. 
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Chapter 1: Introduction 
 
 
Discovery of Sulfonamides 
 
Sulfonamides were the first antimicrobial to be developed and their discovery laid 
the foundation for many of the concepts and techniques used in modern drug discovery. 
They were first discovered in 1932 by German scientist Gerhard Domagk. Working at the 
I. G. Farbenindustrie on methods for staining pathogenic bacteria, Domagk observed that 
an azo dye, Prontosil Rubrum, protected mice and rabbits against lethal doses of 
staphylococci and streptococci, but was ineffective in cell cultures (Domogk, 1935).  It 
was later shown that the azo linkage of Prontosil Rubrum is metabolized by liver 
enzymes to yield the active drug, sulfanilamide, and developed the concept of 
bioactivation (Domogk, 1935) (Figure 1.1A).  During the 1940’s, it was shown that 
addition of para-aminobenzoic acid (pABA) to bacteria colonies could overcome drug 
activity indicating that sulfonamides target the folate biosynthetic pathway (Brown, 
1962). However, it was nearly three decades before Richey and Brown (Richey & Brown, 
1969) demonstrated that sulfanilamide was a potent inhibitor of the folate enzyme 
dihydropteroate synthase (DHPS) by purifying DHPS and performing in vitro analysis 
(Brown, 1962). 
 
DHPS catalyzes the condensation of para-aminobenzoic acid (pABA) and 6-
hydroxymethyl-7,8-dihydropterin-pyrophosphate (DHPPP) to form dihydropteroate, a 
precursor of tetrahydrofolate which is used for DNA synthesis. The sulfonamide group of 
sulfanilamide mimics the carboxyl functional group of pABA. Since sulfur is a more 
electron rich element than carbon, the pKa of the molecule is increased to 10.4 as 
compared to the pABA pKa of ~6.5. Therefore, second generation sulfonamides were 
optimized with the addition of an electron withdrawing ring to lower the pKa making 
them more efficient inhibitors of DHPS (Figure 1.1B). 
 
 
 
 
 
Figure 1.1: Structure of Sulfonamides. A. Schematic representation of prontosil 
metabolism by liver enzymes. B.  Structure of the first and second generation 
sulfonamides. 
A B 
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Sulfonamides and the Treatment of Infectious Diseases 
 
  After their discovery in the early 1930’s, sulfa drugs became widely used and 
served as a first line treatment against bacterial infections. Pharmaceutical companies 
aggressively researched sulfonamides at the outbreak of the Second World War to 
produce potent inhibitors of infectious agents to prevent wound infection. Prisoners at the 
Ravensbrueck concentration camp were used as test subjects by the German army to 
investigate the effectiveness of sulfonamides in preventing infections in open wounds 
(U.S. Holocaust Memorial Museum). As a result of these studies, soldiers were issued 
first aid kits containing sulfa powder which they were told apply to any open wounds 
incurred on the battlefield.  
 
 Sulfa powder, also known as co-trimoxazole, is a combination of 
sulfamethoxazole (SMX) and trimethoprim (TMP). TMP targets the enzyme 
dihydrofolate reductase (DHFR) which catalyzes the reduction of dihydrofolate to 
tetrahydrofolate in the folate pathway downstream of DHPS.  Currently, sulfonamides are 
still an effect treatment for a variety of infectious disease (Table 1.1), but the increase in 
drug resistance has limited their clinical use.  
 
 
Development of Antibiotic Resistance 
 
Historically, sulfonamides have been used as first line treatments for several 
infectious diseases including malaria, leprosy, pneumonia, E. coli, and S. aureus. 
However, antibiotic resistance has emerged as an important factor that severely limits the 
clinical use of sulfonamides (Sköld, 2000; 2001), and resistance mutations in clinical 
isolates of many pathogenic organisms have been characterized (Table 1.2). The most 
common mechanism of acquired resistance has been linked to mutations in the folP gene 
which encodes for DHPS. The majority of these mutations are localized in Loops-1 and -
2 which fold in upon substrate binding to complete the pABA/sulfonamide binding site, 
and primarily affect inhibitor binding. Sulfonamide resistance does not always involve a  
 
 
Table 1.1: Types of Sulfonamides and Therapeutic Uses. 
 
Sulfonamides Therapeutic Indications 
trimethoprim-sulfamethoxazole Treatment and prophalaxis of pneumonia 
 First attack of urinary infection 
pyrimethamine-sulfadiazine Treatment and prophalaxis of cerebral toxoplasmosis 
silver sulfacetamine Prevention/ treatment of bacterial infection for burn 
patients 
sodium sulfacetamie Conjunctivitis and related superficial ocular infections 
sulfadoxine and sulfalene in Chloroquine-resistant malaria 
combination with quinine   
3 
Table 1.2: Resistance Mutations from Clinical Isolates. 
 
Organisms Mutation Observed Corresponding Ba Residue Structure References 
E. coli Phe28Lue, Ile Phe33 Loop 1 Dallas et al., 1992; Fermer & Swedberg, 1997 
N. meningitides Phe31Leu Phe33 Loop 1 Fermer & Swedberg et al., 1997 
P. cariii Phe23Leu Phe33 Loop 1 Lane et al., 1997 
M. leprea Thr53Ile, Ala Thr67 Loop 2 Kai et al., 1999 
P. carinii Thr55Ala Thr67 Loop 2 Lane et al., 1997; Kazanjian et al., 1998; Mei et 
    al., 1998; Wang et al., 1997 
P. falciparum Ser436Ala, Phe Thr67 Loop 2 Wang et al., 1997 
S. pneumoniae Arg58-Pro59 duplication Arg68-Pro69 Loop 2 Kai et al., 1999 
M. leprea Pro55Leu Pro69 Loop 2 Lane et al., 1997; Kazanjian et al., 1998 
P. carinii Pro57Ser Pro69 Loop 2 Mei et al., 1998 
E. coli Pro64Ser Pro69 Loop 2 Vedantam et al., 1998 
S. pneumoniae Arg Insertion after Gly60 Gly70 Loop 2 Padaycahee & Klugman, 1999 
S. pneumoniae Ser61 duplication Phe71 Loop 2 Maskell et al., 1997 
P. carinii His60Asp Ala72 Loop 2 Lane et al., 1997 
S. pneumoniae Ile66-Glu67 duplication Val74-Ser75 Loop 2 Lopez et al., 1987 
P. carinii Ile111Thr Ile122 Loop 4 Lane et al., 1997 
P. falciparum Lys540Glu Asn147 Loop 5 Wang et al., 1997 
N. meningitides 
Gly194Cys, Ser193-
Gly194 Gly188 Loop 6 Fermer et al., 1995; Fermer & Swedberg et al., 
 Duplication   1997 
P. falciparum Ala581Gly Gly190 Loop 6 Wang et al., 1997 
P. falciparum Ala613Ser, Thr Gly224 α7’ Wang et al., 1997 
P. carinii Val248Gly Ile246  α7’ Lane et al., 1997 
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single point mutation, but is often found to contain multiple alterations in the folP gene, 
resulting in changes of up to 10% of the amino acid sequence as compared to sensitive  
isolates (Radstom et al., 1992; Quarnstrom & Swedberg, 2000). 
 
 
DHPS and the Folate Biosynthetic Pathway 
 
 DHPS is a key enzyme in the folate biosynthetic pathway which catalyzes the 
condensation of 6-hydroxymethyl-7,8–dihydropterin-pyrophosphate (DHPPP) with para-
aminobenzoic acid (pABA) in the production of the intermediate dihydropteroate (Figure 
1.2). The pathway serves to generate the cofactor tetrahydrofolate, which is essential to 
all organisms for the metabolic reactions that involve one-carbon transfer such as DNA 
synthesis. Prokaryotes and some lower eukaryotes require these enzymes for folate 
biosynthesis. However, higher eukaryotes utilize high affinity transport systems which 
absorb folate from the gut in the form of folic acid (Matherly, 2001). Therefore, DHPS is 
an ideal drug target because humans do not synthesize folate de novo and is a well 
validated system. Chapter 4 of this thesis deals with our efforts to structurally 
characterize the DHPS enzyme in complex with sulfonamide inhibitors to better 
understand the structural determinants of sulfonamide resistance. 
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Figure 1.2: Schematic Representation of Tetrahydrofolate Synthesis.
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Chapter 2: X-ray Crystallography 
 
 
Introduction 
 
X-ray crystallography is a method of determining the special arrangement of 
atoms within a crystal lattice. Crystals described as regular arrays of atoms which are 
able to scatter X-ray wave, primarily through the atom’s electrons. Using the angles and 
intensities of the scattered beams, a three-dimensional model of the electrons within the 
crystal can be obtained. From the electron density, the mean position of the atoms can be 
determined as well as their chemical bonds. For this reason, x-ray crystal structures are 
useful for shedding light on chemical interactions and processes and serve as a basis for 
designing pharmaceuticals against diseases. Indeed, modern applications of x-ray 
crystallography have led to the development of a new area of research known as 
structure-based drug design. Structure-based drug design is a technique which utilizes 
known molecular structures in conjunction with computational methods to allow a drug 
molecule to be constructed within the biomolecule using knowledge of its structure and 
the nature of its active site.  
 
 
History 
 
Crystals have been scientifically investigated since the 17
th
 century when 
Johannes Kepler hypothesized that the hexagonal symmetry of snowflakes was due to a 
regular packing of water molecules (Kepler, 1611).  After the 18
th
 century, investigation 
by Nicolas Steno (Steno, 1669) and Rene Just Hauy (Hauy, 1784) led to the conclusion 
that crystals can be described by simple stacking patterns of ―blocks‖ of the same shape 
and size. By the mid 19
th
 century, William Hallowes Miller was able to identify crystal 
faces by giving each face a unique label of three small integers known as the Miller 
indices. These studies led to the idea that crystals are a regular three-dimensional array of 
atoms and molecules in a single unit cell which is repeated indefinitely along three 
principle directions. By the conclusion of the 19
th
 century, a complete catalog of possible 
crystal symmetries had been determined and would later be validated by X-ray 
crystallography. 
 
At the turn of the century, Wilhelm Conrad Rontgen discovered X-rays which 
were quickly determined to be waves of electromagnetic radiation. However, X-rays are 
composed of photons, introduced by Albert Einstein, and thus are not only waves of 
electromagnetic radiation but also exhibit particle-like properties (Einstein, 1905). The 
idea to use crystals as a gradient for X-rays arose a collaborative effort between Paul 
Peter Ewald and Max von Laue. The team exposed a sphalerite crystal to an X-ray beam 
and recorded the diffraction pattern onto a photographic plate. Once the plate was 
developed, it revealed a large number of well-defined spots arranged in a pattern of 
intersecting circles around the spot produced by the central beam (Ewald, 1962).   
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From that point on X-ray crystallography boomed. The atomic structure of table 
salt became the first to be solved in 1914 and proved the existence of ionic compounds 
(Bragg, 1914; 1922).  X-ray diffraction was a widely accepted technique in material 
science, chemistry, mineralogy and metallurgy. Discovery after discovery was being 
made to find new ways of utilizing and improving the principle methods of structure 
determination. Soon, organic and biological molecules were being crystallized and 
studied with the work of Dorothy Crowfoot Hodgkin as the premier crystallographer. In 
1964, she was awarded the Nobel Prize in Chemistry for solving the structures of 
cholesterol, vitamin B12, and penicillin. In the late 1950’s, the structure of sperm whale 
myoglobin was solved by Max Perutz and Sir John Cowerdry Kendrew making it the first 
protein structure to be determined via X-ray crystallography. Since then, thousands of 
proteins, nucleic acids, and other biological molecules have been determined using this 
technique.  
 
 
Diffraction Theory 
 
Understanding of how diffraction theory relates to crystal structure determination 
begins by studying the work of William Lawrence Bragg. Bragg proposed a model in 
which a given reflection is associated with a set of evenly spaced sheets running through 
the crystal, usually passing through the centers of the atoms of the crystal lattice. The 
orientation of a particular set of sheets is identified by its Miller indices (h, k, l), and let 
their spacing be noted by a distance, d. Incoming X-rays are scattered in a mirror-like 
fashion from each plane. The X-rays scattered from adjacent planes will combine 
constructively when the angle θ between the plane and the X-ray results in a path-length 
difference that is an integer multiple n of the X-ray wavelength λ. This concept is known 
as constructive interference and can be represented by the formula below.  
 
 
 
Therefore, diffraction only occurs at so called Bragg’s peaks. That is, for an ideal crystal, 
the electron density is perfectly periodic and the Fourier transform, F(q), is zero except 
when q belongs to the reciprocal lattice, that is, to a particular oscillation in the electron 
density in the direction in which q points.  The reciprocal of the reciprocal lattice 
therefore is the original lattice of the crystal.   
 
X-ray crystallography is used to determine the density of electrons f(r) throughout 
a given crystal, where r represents the three-dimensional position vector within the 
crystal. To do this, X-ray scattering is used to collect data about its Fourier transform, 
F(q),  
 
 
where the integral is summed over all possible values of q. The three-dimensional real 
vector q represents a point in reciprocal space. Since the length of q corresponds to 2π 
8 
divided by the wavelength of the oscillation, the following formula for a Fourier 
transform can be used: 
 
where the integral is summed over all possible values of the position vector r within the 
crystal. 
The Fourier transform F(q) has two main components which must be accounted 
for experimentally in order to calculate the electron density of a crystal lattice: a 
magnitude |F(q)| and a phase φ(q) related by the equation, 
 
The intensities of the reflections observed in X-ray diffraction are synonymous with the 
magnitudes |F(q)| but give no information regarding the phases φ(q). To obtain the 
phases, full sets of reflections are collected with known alterations to the scattering, and 
combining the magnitudes and phases yields the full Fourier transform F(q), which may 
be inverted to obtain the electron density f(r). Several methods are available for 
determining phase information. 
 Ab initio phasing, also known as direct methods – Although this method is most 
commonly used for small molecules, it been used successfully to solve the phase 
problems for small proteins. If the resolution of the data is better than 1.4 Å 
(140 pm), direct methods can be used to obtain phase information, by exploiting 
known phase relationships between certain groups of reflections.  
 Molecular replacement – This method is often used if a structure exists of a 
related structure, it can be used as a search model in molecular replacement to 
determine the orientation and position of the molecules within the unit cell. The 
phases obtained this way can be used to generate an electron density maps.  
 Anomalous X-ray scattering (MAD or SAD phasing) – the X-ray wavelength may 
be scanned past an absorption edge of an atom, which changes the scattering in a 
known way. By recording full sets of reflections at three different wavelengths 
(far below, far above and in the middle of the absorption edge) one can solve for 
the substructure of the anomalously diffracting atoms and thence the structure of 
the whole molecule. The most popular method of incorporating anomalous 
scattering atoms into proteins is to express the protein in a methionine auxotroph 
(a host incapable of synthesising methionine) in a media rich in Seleno-
methionine, which contains Selenium atoms. A MAD experiment can then be 
conducted around the absorption edge, which should then yield the position of 
any methionine residues within the protein, providing initial phases.  
9 
 Heavy atom methods (i.e., MIR) – If electron-dense metal atoms can be 
introduced into the crystal, direct methods or Patterson-space methods can be 
used to determine their location and to obtain initial phases. Typically, heavy 
atoms may be introduced either by soaking the crystal in a heavy atom-containing 
solution, or by co-crystallization (growing the crystals in the presence of a heavy 
atom). As in MAD phasing, the changes in the scattering amplitudes can be 
interpreted to yield the phases. Although this is the original method by which 
protein crystal structures were solved, it has largely been superseded by MAD 
phasing with selenomethionine. 
In addition, for every reflection corresponding to a point q in the reciprocal space, 
there is another reflection of equal intensity at the opposite point −q. This opposite 
reflection is known as the Friedel pair of the original reflection. This symmetry results 
from the mathematical fact that the density of electrons f(r) at a position r is always a real 
number. As noted above, f(r) is the inverse transform of its Fourier transform F(q); 
however, such an inverse transform is a complex number. To ensure that f(r) is real, the 
Fourier transform F(q) must be such that the Friedel pairs F(−q) and F(q) are complex 
conjugates of one another. Thus, F(−q) has the same magnitude as F(q)— that is, |F|(q) = 
|F|(−q)—but they have the opposite phase, i.e., φ(q) = −φ(q): 
 
 
The equality of their magnitudes ensures that the Friedel pairs have the same intensity 
|F|
2
. This symmetry allows one to measure the full Fourier transform from only half the 
reciprocal space. In crystals with significant symmetry, even more reflections may have 
the same intensity. In such cases, even less of the reciprocal space may need to be 
measured. 
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Chapter 3:  Structural Studies of the Dihydropteroate Synthase (DHPS) 
 
 
Background 
 
 There are currently five known structures of DHPS: B. anthracis (Babaoglu et al., 
2004), E. coli (Achari et al., 1997), S. aureus (Hampele et al., 1997), M. tuberculosis 
(Baca et al., 2000), and S. Pneumoniae (Levy et al., 2008) as well as the structure of the 
S. cerevisiae DHPS (Lawrence et al., 2005) which is fused to an additional enzyme of the 
folate pathway, 6-hydroxymethyl-7,8-dihydropterin pyrophosphokinase (HPPK).  The 
DHPS enzyme is a classic (α/β)8 TIM barrel. Several structures of DHPS in complex with 
6-hydroxymethyl-pterine-pyrophosphate (PtPP) and 6-hydroxymethyl-pterin-
monophosphate (PtP) have been reported (Hampele et al., 1997; Baca et al., 2000; 
Babaoglu et al., 2004; Levy et al., 2008) and the pterin binding site is well characterized 
(Figure 3.1A,B).  In addition, the structure of DHPS complexed with pteroic acid, a 
product analog, has been reported (Babaoglu et al., 2004) which revealed for the first 
time the position of the pABA binding site (Figure 3.1C). These structures build a 
preliminary model of the DHPS active site in which pterin binds into a highly conserved, 
rigid pocket buried deep within the DHPS enzyme (Figure 3.1D). In contrast, pABA 
binds to a surface region of the enzyme composed mainly of flexible loop regions which 
stabilize upon substrate binding to complete the active site. Based on the PtPP and PtP 
structures, Baca et al proposed a SN2 transition-state shown in Figure 3.2. In addition, it 
has been shown that substrate binding into the DHPS active site proceeds via an ordered 
mechanism where pABA binding is dependent upon the presence of bound DHPPP 
(Babaoglu et al., 2004; Levy et al., 2008). Levy et al. demonstrated that pyrophosphate 
was efficient to facilitate pABA binding in the absence of a pterin moiety correlating to a 
SN2 mechanism.   
 
These structural studies show that the DHPS active site is divided into two 
separate, distinct regions: the pABA binding site and the pterin binding site. The pterin 
binding site is a highly conserved pocket embedded within the core of the DHPS 
structure and is composed of four key interactions with surrounding residues (Figure 
3.1A,B,C): Arg254 pi-stacking interactions, Asn120 H-acceptor, Asp184 H-acceptor, and 
Lys220 H-donor. Upon pterin binding, Lys220 extends to form a platform for pABA to 
bind as indicated in the pteroic acid structure (Figure 3.1C). pABA is also stabilized in 
the active site by an H-bonding interaction with Ser221. In addition, Levy et al. 
demonstrated that Loops-1 and -2 fold in upon pterin binding to complete the pABA 
binding site. However, these loop interactions have yet to be structurally characterized. 
Since the pterin binding pocket is highly conserved (Figure 3.3), it seems logical that it 
would be more difficult for the enzyme to accommodate mutations against pterin-based 
compounds. In addition, mutations that could potentially cause resistance to pterin-based 
inhibitors are likely to disrupt structural integrity since the pterin binding site is buried 
within the protein. In contrast, the pABA binding site involves flexible loop regions near 
the surface of the protein, and the rapid emergence of multiple sulfonamide resistance 
mutations clearly show that they are easily tolerated within the overall structure of the 
11 
 
 
 
Figure 3.1: Structure of the DHPS Active Site. A. DHPS active site with bound PtP 
(PDB: 1EYE). Red arrow shows the direction of nucleophilic attack proposed by Baca et 
al. and the green arrow represents the direction of nucleophilic attack indicated by the 
pteroic acid structure. B. DHPS active site with bound PtPP (PDB: 1TWS). C. DHPS 
active site with bound pteroic acid. Compound source of structure: Babaoglu, K., Qi, J., 
Lee, R.E. and White, S.W. (2004). Crystal structure of 7,8-dihydropteroate synthase from 
Bacillus anthracis : mechanism and novel inhibitor design. Structure, 12 :1705-1717. D. 
Surface representation of DHPS active site with bound pteroic acid indicating the 
separate binding pockets for each substrate. Note that the pterin moiety is deeply 
imbedded within the protein structure. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2: Schematic Representation of the DHPS Transition State. 
A 
B 
C D 
12 
 
 
 
 
Figure 3.3: DHPS Sequence Alignment. The ― ‖ means that the residues in that column 
are identical in all sequences in the alignment. The ―:‖ means that conserved substitutions 
have been observed. The ―.‖ means that semi-conserved substitutions have been 
observed. Residues known to interact with pterin moiety are in red.  
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protein. It is a long term goal of this project to develop new inhibitors of DHPS which 
target the pterin binding site. 
 
 
Results 
 
 While much of the DHPS active site has been structurally elucidated, key 
interactions involving Loops-1 and -2 have yet to be determined. Therefore, it is the 
purposes of this study to construct a more desirable model by which to study these loop 
interactions. Analysis of the wild type B. anthracis structure revealed crystal packing 
interactions involving Loops-1 and -2. As shown in Figure 3.4, Loop-1 is engaged in an 
intramolecular packing interaction involving Phe33. Based on the M. tuberculosis 
structure (Baca et al., 2000), Loop-1 is a central component of the active site, and any 
movement of the loop would most likely destroy the crystals. Also, Phe33 has been 
shown to be a resistance mutation in drug resistant strains of N. meningitides and E. coli 
(Table 1.2). Loop-2, on the other hand, is folded into the pterin biding pocket forming π-
stacking interactions with Arg254 (Figure 3.5). These interactions bind the loops into 
artificial conformations which prevent them from folding into the active site and, thereby, 
hindering a functional conformation of these loops in structural studies. Several residues 
located on Loop-2 have been shown to be involved in resistance mutations as well (Table 
1.2). For these reasons, we have used site-directed mutagenesis techniques on surface 
residues to break crystal packing interactions in an attempt to grow a different crystal 
form in which these loops are free to interact with substrates upon binding. Analysis of 
the crystal lattice led to the following mutations: Tyr39His and His137Glu (Figure 3.6). 
These mutations were made based on the Y. pestis sequence. Furthermore, biochemical 
studies using the radio-labeled assay (Materials and Methods) showed no significant 
change in catalytic activity (data not shown). 
 
 After several crystal trials, crystals were found in a 1.5M sodium malonate pH = 
5.00 condition (Figure 3.7A). The outward appearances of these crystals were strikingly 
different from the wild type crystals grown by Babaoglu which were grown in a 1.3 M 
Li2SO4, 0.1 M Bis-Tris propane, pH 9.0 condition (Figure 3.7B) indicating that the 
mutations were successful in yielding an alternative crystal packing arrangement. 
Crystals of the DM construct were grown in space group P212121 with unit cell 
dimensions a = 100.3 Å, b = 107.9 Ǻ, c = 243.4 Ǻ, and the structure was solved to 2.0 Å 
resolution by molecular replacement using the wild type B. anthracis structure as a search 
model. Superposition of the double mutant structure showed no major conformational 
changes in the protein architecture (data not shown). 
 
Presented here is the crystal structure of the double mutant (DM) B. anthracis 
DHPS (Figure 3.8). Analysis of the structures using PROCHECK (Laskowski et al., 
1993) showed that each has excellent stereochemistry and final R-factors that are 
appropriate for their resolutions. Structure statistics are shown in Table 3.1.  These 
structures are comparable to the native DHPS structures preciously determined. There are 
no significant differences apart from the conformation of loops and residues which 
compose the actives site regions. There is no electron density for the N-terminal 
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Figure 3.4: Crystal Packing Interactions Involving Loop-1.  
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Figure 3.5: Crystal Packing Interactions Involving Loop-2. A. This structure shows pterin binding into the pterin-pocket. B. This 
structure shows Arg68 binding into the pterin-pocket. Compound source of structure: Babaoglu, K., Qi, J., Lee, R.E. and White, S.W. 
(2004). Crystal structure of 7,8-dihydropteroate synthase from Bacillus anthracis : mechanism and novel inhibitor design. Structure, 
12 :1705-1717.  
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Figure 3.6: Analysis of WT B. anthracis Crystal Packing. A. Crystal packing interactions between monomers A and B. B. Crystal 
packing interactions between symmetry mates. C. Crystal packing interaction involving Tyr39.  D. Crystal packing interaction 
involving His137. 
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Figure 3.7: Crystals of the B. anthracis DHPS. A. Crystals of the double mutant 
construct. B. Crystals of WT B. anthracis.  
 
 
 
 
 
Figure 3.8: Active Site with Functional Conformation of Loop-2. A. This view shows 
stabilized Loop-2 with Arg68 directed towards the pABA binding site. Residues in green 
are involved in drug resistance. B. This view shows the DM Loop-2 (orange) with pteroic 
acid product analogue modeled in to the active site as well Loop-2 conformation from S. 
aureus (yellow) and Loop-1 conformation from M. tuberculosis (purple). 
 
 
 
 
 
 
 
 
 
 
 
S. aureus 
DM B. anthracis 
M. tuberculosis 
B A 
Gly188 
Arg68 
Thr67 
Pro69 
A B 
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Table 3.1: Crystallization Data of the DHPS Double Mutant Construct. 
 
Data Collection  DM Construct 
Space Group P212121 
Cell Dimensions  
a,b,c (Å) 100.357, 107.999, 243.443 
α,β,γ (°) 90,90,90 
Resolution (Å) 50-2.4 
Rsym or Rmerge 9.3 (65.6) 
I/ σI 12.2 (1.5) 
Completeness (%) 98.4 (87.0) 
Redundancy 6.7 (3.1) 
Refinement Resolution (Å) 50-2.6 
No. Reflections 113375 
Rwork/ Rfree 20.1/ 25.6 
No. Atoms  
Protein 15912 
Ligand/ Ion 120 
Water 784 
Ramachandran Plot  
Most favored (%) 88.4 
Additional allowed (%) 10.6 
Generously allowed (%) 0.5 
Disallowed (%) 0.5 
R.M.S. deviation  
Bond lengths (Å) 0.010 
Bond angles (°) 1.500 
 
 
Note: Values in parenthesis correlate to the highest resolution shell. 
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methionine, the N-terminal 6xHis tag, or the final three C-terminal residues in any of the 
structures. 
 
The overall fold of the B. anthracis DHPS has been described in previous works 
(Babaoglu et al., 2004). The basic fold of the protein is a classic (β/α)8 TIM barrel 
(Banner et al., 1975) in which repeating β/α units create an eight-stranded parallel β-
barrel surrounded by eight α-helices.  In TIM barrel enzymes, the active site is located at 
the C-terminal pole of the β-barrel and completed by interactions with surrounding, 
flexible loop regions. The same is true for DHPS, however, there is some debate as to the 
correct functional conformation of these loops as significant variations in conformation 
have been reported in the various orthologs.  
 
Loop-1 (residues 29-37) is highly conserved, but is not fully visible in any of the 
eight monomers in the double mutant structure. Although it is highly conserved, its 
conformation is reportedly highly variable which indicates that Loop-1 is a highly mobile 
region of the DHPS active site. This would explain why Loop-1 is not visible in our 
structure as well as monomer B of the WT B. anthracis structure and one monomer of the 
S. aureus structure. 
 
Loop-2 (residues 63-64) is also a highly conserved loop in the DHPS structure 
and is visible in three of the eight monomers of the asymmetric unit. It adopts a bent 
conformation (Figure 3.8A) in which R68 points towards the binding position of the  
carboxyl group of pABA. We believe that this conformation of Loop-2 is of functional 
significance and aids in stabilizing pABA in the active site.  
 
By modeling in the pteroic acid structure from the wild type B. anthracis complex 
(Babaouglu et al., 2000), we can visualize how this Loop-2 conformation may interact 
with the carboxylic acid of pABA.  Furthermore, modeling in the various loop 
conformations from the M. tuberculosis and S. aureus structures sheds light on how these 
loops are able to move and assist one another to facilitate substrate binding (Figure 3.8B). 
 
The double mutant construct also yields several implications into the mechanism 
of drug resistance. Specifically, the structure reveals the position of four key resistance 
mutation sites. First, it shows the position of Thr67 located on Loop-2 which is mutated 
to an Alanine in P. carinii and M. leprea mutant alleles (Figure 3.8A; Table 1.2). Second, 
the structure reveals the position of Pro69 also on Loop-2 (Figure 3.8A) which is mutated 
to a Serine in P. carinii and E. coli mutant alleles (Table 1.2) as well as the position of 
Arg68 on Loop-2. Furthermore, the apparent flexibility of Loop-2 suggests that Pro69 
and Thr67 function to structurally stabilize Loop-2 in order to direct Arg68 towards the 
active site. Finally, the structure reveals the location Gly188 on Loop-6. Gly188 is 
mutated to Cysteine in N. meningitides drug resistant alleles (Table 1.2). The position of 
Gly188 suggests that the Gly188Cys mutation may function by sterically hindering the 
binding of sulfamethoxazole into the DHPS active site. 
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Chapter 4: Kinetic Studies of DHPS 
 
 
Background 
 
Current structural studies (see Chapter 3) build a preliminary model of the DHPS 
active site in which pterin binds into a highly conserved, rigid pocket buried deep within 
the DHPS enzyme. In contrast, pABA binds to a surface region of the enzyme composed 
mainly of flexible loop regions which stabilize upon substrate binding to complete the 
active site. Based on the PtPP and PtP structures, Baca et al proposed a SN2 transition-
state. In addition, it has been shown that substrate binding into the DHPS active site 
proceeds via an ordered mechanism where pABA binding is dependent upon the presence 
of bound DHPPP (Babaoglu et al., 2004; Levy et al., 2008). Levy et al. demonstrated that 
pyrophosphate was efficient to facilitate pABA binding in the absence of a pterin moiety 
correlating to a SN2 mechanism.  However, the pABA binding site predicted in the 
pteroic acid structure seemingly contradicts the SN2 mechanism as the direction of the 
nucleophilic attack is not optimal.  
 
Understanding the mechanism of DHPS catalysis is particularly important for 
understanding the mode of sulfonamide resistance since sulfonamides inhibit the function 
of DHPS by competing with pABA for active site binding (Brown, 1962). However, in 
many instances these compounds undergo catalytic activity to produce sulfa-pterin 
adducts (Roland et al., 1979; Patel et al., 2004; Valderas et al., 2008) which have been 
implicated as inhibitors of dihydrofolate reductase (DHFR) (Patel et al., 2004). DHFR is 
an enzyme downstream of DHPS in the folate pathway and is the target for several 
inhibitors commonly used in synergism with sulfonamides. Historically, sulfonamides 
have been used as first line treatments for several infectious diseases including malaria, 
leprosy, pneumonia, E. coli, and S. aureus. However, drug resistance has emerged as an 
important factor that severely limits the clinical use of sulfonamides (Sköld, 2000; 2001), 
and resistance mutations in clinical isolates of many pathogenic organisms have been 
characterized. The majority of these mutations are localized in Loops-1 and -2 which fold 
in upon substrate binding to complete the pABA/sulfonamide binding site.  For this 
purpose, we have developed a radiometric assay to understand the involvement of Loops-
1 and -2 in the development of sulfonamide resistance.  
 
 
Results 
 
We have developed two assays to be used for kinetic studies, ELIPA (enzyme 
linked inorganic phosphate assay) and a radio-labeled assay. In the ELIPA, 
pyrophosphate released during the condensation of DHPPP and pABA is broken down 
into inorganic phosphate by a pyrophosphatase. The inorganic phosphate then reacts with 
2-amino-6-mercapto-7-methylpurine riboside (MESG) to produce mercapto-
methylpurine and ribose-1-phophate. Since the absorption ranges of MESG (330 nm) and 
mercato-methylpurine (360 nm) are different, the amount of pyrophosphate released can 
be measured by observing an increase in absorption at 360 nm over time. Therefore, the 
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results of the ELIPA experiment correlate to the amount of phosphate released during 
catalysis. Two reactions were tested by this method: the reaction DHPPP + pABA and 
the reaction of DHPPP + SMX (sulfamethoxazole) in the absence of pABA. As shown in 
Figure 4.1, both reactions show a comparable release of phosphate indicating that SMX is 
able to undergo enzymatic catalysis. While these results reveal a unique characteristic of 
the sulfonamide class of drugs, they limit the use of the ELIPA experiment for studies in 
antibiotic resistance. To overcome this issue, we developed a radio-labeled assay using 
14
C pABA as one of the substrates and monitoring the appearance of 
14
C-labeled product 
by thin-layer chromatography (Nopponpunth et al., 1999; Kasekarn et al., 2004).  
 
 The radiometric assay was used to measure the kinetic parameter Km and Kcat of 
mutated DHPS enzymes. Several types of sulfonamide resistance determinants have been 
identified (Sköld, 2000; 2001). Five point mutations were identified and chosen for this 
study (P69S, T67A, R68A, G188C, and F33L) based on the relative position to either 
Loop-1 or Loop-2.  Each mutated strain was mutated from the WT strain of B. anthracis 
using site-directed mutagenesis as described in Material and Methods. Mutations P69S, 
T67A, R68A, and G188C all show an increase in Km and Kcat values as compared to the 
WT enzyme indicating that the enzyme must lower efficacy to accommodate sulfonamide 
resistance (Table 4.1). The mutation F33L showed no activity in vitro as compare to the 
WT enzyme (Table 4.1; Figure 4.2). However, an extensive literature search yields 
reports of clinical isolates with this specific mutation (Dallas et al., 1992; Fermer & 
Swedberg, 1997). Furthermore, these isolates were obtained from sulfonamide resistance, 
pathogenic strains (Dallas et al., 1992; Fermer & Swedberg, 1997; Lane et al., 1997). 
 
 
 
 
 
Figure 4.1: Results from the ELIPA Experiment.
pABA :       + 32uM [DHPPP]  + 30uM [pABA] 
control :      + 32uM [DHPPP]   
SMX-50 :    + 32uM [DHPPP]  + 50uM [SMX] 
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Table 4.1: Kinetics Studies of Mutant Alleles. 
 
 Construct Km (μM) Kcat (min
-1
) 
SMX SNA 
IC50 (μM) Ki (μM) IC50 (μM)) Ki (μM) 
WT 0.3370 (± 0.1263) 21.82 (± 2.17) 2.258 (± 0.232) 0.143 (± 0.014) 18.52 (± 1.72) 1.169 (± 0.108) 
P69S 5.751 (± 2.454) 7.000 (± 1.43) 5.196 (± 0.434) 2.779 (± 0.232) 39.88 (± 3.61) 21.33 (± 1.93) 
T67A 0.5823 (± 0.200) 11.16 (± 1.02) 10.26 (± 0.95) 1.070 (± 0.099) 315.5 (± 72.0) 32.91 (± 7.50) 
R68A 1.523 (± 0.719) 13.43 (± 2.31) 0.881 (± 0.064) 0.206 (± 0.015) 13.42 (± 1.406) 3.133 (± 0.328) 
G188C 0.699 (± 0.250) 7.29 (± 0.83) 7.1754 (± 1.653) 0.880 (± 0.203) 31.24 (± 5.96) 3.831 (± 0.731) 
F33L > 50 N/A N/A N/A N/A N/A 
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Figure 4.2: Results from the Radiometric Assay.  
 
 
In order to understand our results, we verified that the mutation was successful. 
To do so, we isolated the plasmid of interest and sequenced the gene by the dideoxy 
chain-termination method for sequencing DNA. These results were then aligned with the 
wild type sequence and analyzed for the appearance of mutations. As seen in Figure 4.3, 
the alignment revealed that the triad TTT encoding for Phenylalanine 33 was indeed 
mutated to a CTG encoding for a Leucine. Therefore, the mutation was correct and the 
results observed in the radiometric assay correlate to a F33L mutation. 
 
 In addition to Km and Kcat studies, IC50 values in the presence of sulfamethoxazole 
(SMX) were determined for each mutant enzyme as well as IC50 values in the presence 
sulfanilamide (SNA). Mutations P69S, T67A, R68A, and G188C all showed an increase 
in IC50 values as compared to WT in the presence of both SMX and SNA (Table 4.1). 
However, the ability was amplified against SNA as compared to SMX indicating that the 
terminal ring of SMX may be hindering the enzyme’s ability to develop drug resistance 
while maintaining a viable enzyme. This data showed that the T67A mutation has the 
most pronounced effect upon developing drug resistance while having the least effect on 
the catalytic efficacy of the enzyme. In contrast, R68A and P69S mutations seem to offer 
little sulfonamide resistance in light of a five fold or better loss in the catalytic efficacy. 
These results yield a great deal of insight into the catalytic mechanism of the enzyme as 
well as key residues necessary for catalysis, namely P69, R68, and F33 all of which are 
highly conserved residues in the DHPS sequence. 
 
 In addition to the kinetic studies, we have performed preliminary structural 
studies of the mutant alleles. We have successfully crystallized P69S, F33L, and T67A 
mutants (Figure 4.4), but we have not been able to visualize Loops-1 or -2 in these crystal  
14
C pABA 
14
C product 
14
C pABA 
WT 
DHPS 
F33L 
DHPS 
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Figure 4.3: F33L Sequence Verification.  
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Figure 4.4: Crystallization of the P69S, T67A, and F33L Mutant Alleles.  
 
 
   
 
 
P69S T67A F33L 
26 
structures. Attempts have been made to co-crystallize these mutant enzymes with pteroic 
acid, but with no success to date.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
27 
Chapter 5: Discussion 
 
 
The Conformation and Roles of Loops-1 and -2 
 
 In all known crystal structure of DHPS, including the double mutant construct 
reported in this thesis, Loops-1 and -2 adopt highly variable conformations or are missing 
all together. This observation suggests that these loops are highly mobile and work in an 
ordered manner to aid in substrate binding and stabilization. As regards to Loop-1, we 
can offer no new structural insights into the why it is so conserved. Based on the M. 
tuberculosis structure, Loop-1 can fold in such a way as to allow key residues such as 
Asp35 to interact with the pABA binding sight. Our kinetics data reiterates the 
importance of Loop-1 for pABA binding by revealing that Phe33 is essential to the 
catalytic efficacy of the enzyme.  
 
 The conformation of Loop-2 that we present in the DHPS double mutant construct 
is unique amongst the known DHPS structures. By modeling in the pteroic acid product 
analogue, our structure reveals that the side chain of conserved Arg68 bends towards the 
carboxylic acid component of pABA to stabilize it in the binding site. Babaoglu et al. 
reports that Arg68 folds into the pterin binding sight to give added stability to the 
unliganded enzyme. This report in conjunction with our data suggests that Arg68 may 
function to ensure pABA can only bind if the pterin substrate is already bound into the 
active sight. The suggested binding of pABA between ordered Loops-1 and -2 would 
essentially block the pterin pocket, thereby preventing pterin from binding into the active 
site. This is further confirmed by previous reports that enzyme catalysis proceeds via an 
ordered mechanism in which bound pterin is required for pABA binding (Vinnicombe & 
Derrick, 1999; Levy et al., 2008).  Our structure shows for the first time a functionally 
significant conformation of Loop-2 and the role of Arg68 in enzyme catalysis.  
 
 
Implications of Sulfonamide Resistance 
   
 Antibiotic resistance is the ability of a microorganism to overcome the effects of a 
particular drug due to genome modifications. This process occurs via natural selection in 
which random point mutations lead to natural selection of a drug resistant gene. Such 
genes can then be inserted in to the pathogen genome via horizontal gene transfer (Ochiai 
et al., 1959).  Introduction of antibiotic action against a pathogen creates an 
environmental stress in the system. Bacteria which have the mutation allowing them to 
survive will reproduce ensuring that the advantageous gene mutation is passed on to their 
offspring (Figure 5.1). The result is a fully resistant colony.  
 
 Microorganisms are able to exhibit antibiotic resistance in a variety of ways. The 
four most common modes of resistance development are as follows: drug inactivation or 
modification, alteration of target site, alteration of metabolic pathway, and reduced drug 
accumulation. 
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Figure 5.1: Schematic Representation of the Formation of Antibiotic Resistant Colonies. 
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This study clearly shows that specific point mutations in the target site of 
sulfonamide binding leads to a decrease in binding affinity of sulfonamides. Specifically, 
mutations which disrupt the structural stability of Loops-1 and -2 have significant effects 
on drug binding which ultimately lead to antibiotic resistant bacterial strains.  This 
evidence suggests that these flexible loop regions of the DHPS enzyme can readily 
accommodate point mutations while maintaining a functionally viable enzyme. 
Therefore, it is important to avoid such regions during the development of novel 
therapeutics which target the DHPS enzyme. 
 
 
The Catalytic Mechanism of DHPS 
 
 By docking in the pteroic acid structure into our new DHPS structure with a 
functionally significant conformation of Loop-2, it is possible to generate a model of the 
DHPS catalytic mechanism (Figure 3.8).  This model shows that SMX binds to the DHPS 
active site in a similar fashion as pABA and this interaction is facilitated by Arg68 as 
well as additional components of Loop-2. Furthermore, the position of SMX in the active 
site reiterates the proposed SN2 mechanism previously reported by Babaouglu and 
colleagues.  
 
 Based on previous data in conjunction with the data presented in this thesis, we 
propose that the mechanism proceeds by four steps via an ordered mechanism. In the 
initial state, Arg68 is bound into the pterin pocket as seen by Babaouglu and colleagues. 
During the first step, DHPP binds into the active site (Vinnicombe & Derrick, 1999; Levy 
et al., 2008) displacing Arg68 from the pterin pocket. This causes a conformational shift 
of Loop-2 which can easily be envisaged by comparing our new Loop-2 conformation 
with those of previously reported conformations in the E. coli and S. aureus structures.  
Facilitated by the pterin moiety, the β-phosphate enters the anion binding pocket and the 
divalent cation binding site involving Asn27 from Loop-1 becomes occupied by the 
Mg2+ ion that coordinates the pyrophosphate for an SN2 reaction.  Indeed, the divalent 
cation may aid in drawing Loop-1 into the active site and thereby bringing Phe33 with it. 
The second step creates the pABA binding site. Formation of the pABA binding site is 
facilitated by the binding of the DHPP and the binding of Lys220 to the pterin moiety. 
Lys220 stretches to form a platform by which pABA can dock into the active site. As 
Lys220 swings out it exposes the N-terminal end of helix α-Loop-7 for additional 
hydrogen binding interactions. The pABA binding site is completed by movement in 
Loops-1 and -2, and Arg68 in its new conformation seen in the Pt-SMX structure now 
interacts with pABA via charge interactions and π-stacking interactions. The third step 
involves nucleophilic SN2 attack by the nitrogen group of pABA on the methyl carbon 
on the C6 position of DHPP. The divalent ion coordinates the pyrophosphate and 
functions to make it a better leaving group facilitating an SN2 attack. During the final 
step, Loop-2 reinserts into the pterin pocket and product is released for further 
modification down the metabolic pathway. The enzyme is then ready to repeat the 
enzymatic mechanism with new substrate. Table 5.1 depicts all the residues believed to 
be involved in the catalytic mechanisms as well as synonymous residues in different 
organisms. The residues colored red represent those with sequence variance as compared  
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Table 5.1: Sidechains Involved in Substrate Binding. 
 
B. anthracis Interaction Type E. coli S. aureus M. tuberculosis S. pneumoniae P. aeruginosa 
Thr67   Thr62 Thr51 Ser53 Thr57 Ser49 
Arg68 H-donor/ Pi Electronics Arg63 Arg52 Arg54 Arg58 His50 
Asp101  Asp96 Asp84 Asp86 Asp91 Asp82 
Asn120 H-acceptor Asn115 Asn103 Asn105 Asn110 Asn101 
Ile122 vDW Ile117 Gln105 Val107 Ile112 Ile103 
Ile143 vDW Cys137 Val126 Val128 Val133 Val123 
Met145 Pi Electronic Met139 Met128 Met130 Met135 Met125 
Asp184 H-acceptor Asp185 Asp167 Asp177 Asp201 Asp173 
Phe189 Pi Electronic Phe190 Phe172 Phe182 Phe206 Phe178 
Leu214 vDW Leu215 Leu197 Leu207 Phe231 Leu206 
Gly216  Gly217 Ala199 Gly209 Gly233 Ser208 
Lys220 H-donor Lys221 Lys203 Lys213 Lys237 Lys212 
Arg254 Pi Electronic Arg255 Arg239 Arg253 Arg282 Arg246 
 
 
 Note: Residues in red are those that diverge from the B. anthracis sequence 
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to the B. anthracis sequence. In addition, the table shows the types of interactions each 
residue participates in upon substrate binding.  
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Chapter 6: Materials and Methods 
 
 
Cloning of the folP Gene 
 
 The anthrax folP gene encoding DHPS was obtained by PCR amplification using 
genomic DNA obtained from the Sterne 34F2 strain of Bacillus anthracis as described in 
Babaouglu et al., 2004. The following primers, with inserted restriction sites in italics, 
were designed using the sequence from the A2102 strain deposited in the NCBI database 
(gi:21397375): 5’ NdeI: CATATGAAGTGGGATTATGATTTGCGC and 3’ BamHI: 
GGATCCTTACTTTACCCCTTACCAATCATCGC. 
 
 Three reactions were set up using the High Fidelity supermix kit (Invetrogen, 
Carisbad, CA) and the protocol suggested in the product literature. The PCR reaction 
consisted of an additional heating step for 2 min. at 94°C followed by 25 cycles of 30 sec. 
at 94°C, annealing at 53°C for 30 sec., and extension at 72°C for 2 min. The PCR 
products were analyzed on a 1% agarose gel stained with ethidium bromide to identify 
the amplification species of the appropriate size (846 bp). The PCR products were 
purified, subcloned using the TOPO TA cloning kit (Invitrogen, Carlsbad, CA) into the 
pCR 2.1 TOPO vector, and finally sequenced to ensure that the restriction during the 
PCR reactions. Primer synthesis and DNA sequencing were performed by the Hartwell 
Center at St. Jude Children’s Research Hospital.  
 
 
Protein Expression and Purification 
 
The folP gene encoding DHPS was obtained and subcloned from the TOPO TA 
vector into the pET-28a expression plasmid (Novagen, Madison, WI) that incorporates a 
6xHis Tag at the N terminus of the expressed protein (Babaoglu et al., 2000). Two 
surface residues were mutated using Quickchange
®
 (Stratagene, La Jolla, CA) site-
directed mutagenesis. The plasmid was then transformed into competent BL21 (DE3) E. 
coli cells (Stratagene) for expression. A 100mL overnight culture was grown form a 
single colony of cells in LB containing 50 μg/ml kanamycin, and this culture was used to 
inoculate 6 L. of the same medium. This was grown at 37°C until the OD600 reached ~0.6, 
at which point isopropyl-β-D-thiogalactopyranoside (IPTG) was added to a final 
concentration of 1 mM. Cell were then allowed to grow overnight at 16°C in the presence 
of IPTG and then harvested by centrifugation. The cell pellet was resuspended in 50 ml 
lysis buffer (20 mM NaPO4, pH 8.0, 0.5 mM NaCl, and 1mM Imidazole). The cells were 
lysed by a microfluidizer, and the cell debris was cleared by centrifugation at 30,000 x g 
for 1 hour. 
 
 Purification of DHPS required two steps of Fast Performance Liquid 
Chromoatography (FPLC), Ni2+ chelation affinity chromatography and gel filtration. 
The cell lysate was first applied to a 5 ml HiTrap Chelating HP column (Amersham 
Biosciences, Piscataway, NJ) and washed with ten column volumes of lysis buffer. The 
protein eluted during a gradient of 0-0.3 M imidazole, and the appropriate fractions were 
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identified by SDS-PAGE. The pooled DHPS was concentrated to 3 ml, applied to a 
HiLoad 16/60 Superdex 75 column (Amersham Biosciences), and eluted with running 
buffer (20 mM NaPO4, pH 8.0, 0.2 M NaCl, 1 mM dithiothreitol (DTT), and 1 mM 
MgCl2) at a flow rate of 0.5 ml/min. The final purified protein was estimated to be >95% 
pure by SDS-PAGE analysis.  
 
 
Crystallization and Data Collection 
 
The purified enzyme was concentrated with an Amicon stirred cell to a final 
concentration of 10 mg/ml. Using the hanging drop vapor diffusion method together with 
Hampton Crystal Screens kits (Aliso Viejo, CA), a number of initial crystallization 
conditions were identified by mixing equal volumes (2 μl) of protein to well solution. 
These conditions were subsequently optimized, and large well-diffracting crystals could 
eventually be grown from 1.8 M Sodium Malonate. Large rectangular box shaped 
crystals could be obtained within 72 hrs at 18°C. The crystals are in space group P212121 
with cell dimensions a = 100.357 Å, b = 107.999 Å, c = 243.443 Å. Consideration of the 
Mathews coefficient suggested that eight molecules of DHPS should be present in the 
asymmetric unit, and this was subsequently confirmed. For the structural studies of 
pterin-sulfamethoxazole (Pt-SMX), the compounds were directly added to pregrown 
crystals in the form of saturated solution in the crystallization buffer, and allowed to soak 
for 72 hrs.  
 
 All x-ray diffraction data were collected under cryogenic conditions. Crystals 
were briefly immersed in a cryoprotectant mixture of 25% glycerol and directly flash 
frozen in liquid nitrogen. All data were collected at the Southeast Regional Collaborative 
Access Team (SER-CAT) synchrotron beamline 22-ID and 22-BM at the Advanced 
Photon Source (Argonne National Laboratory). All crystals were frozen and prescreened 
in-house before synchrotron data collection. The DHPS-PtSMX synchrotron data were 
collected on a MAR300 CCD detector and processed and merged using HKL2000 
(Otwinowski & Minor, 1997). All relevant data collection statistics are shown in Table 
3.2. 
 
 
Structure Determination 
 
The structure of the double mutant DHPS from B. anthracis was determined by 
molecular replacement using the CCP4 program Phaser (McCoy et al., 2007). Monomer 
A of the wild-type B. anthracis structure (PDB: 1TWS) was used as an initial search 
model. A solution was obtained using high resolution synchrotron data and refined 
following several iterative rounds of rebuilding in COOT (Emsley & Cowtan, 2004), and 
simulated annealing and temperature factor refinement using CNS (Brüger et al., 1998). 
All the waters were picked automatically using COOT and subsequently confirmed by 
visual inspection. Finally, to verify ambiguous regions of the electron density and to 
check the model, a number of simulated annealing omit maps were calculated during the 
later stages of the refinement process. The quality of the structure was verified using 
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PROCHECK (Laskowski et al., 1993), and the final refinement statistics are shown in 
Table 3.1. 
 
 
Radiometric Assay 
 
 To observe enzyme kinetics, we developed a radio-labeled assay using 
14
C pABA 
as one of the substrates and monitoring the appearance of 
14
C-labeled product by thin-
layer chromatography (Nopponpunth et al., 1999; Kasekarn et al., 2004). For the first 
reaction (synthesis of DHPPP), the substrate (10 μM of HMDP) was incubated in 
presence of ATP (250 μM), MgCl2 (10 mM), and HPPK enzyme (10 μg) at 37
o 
C for 30 
minutes. The reaction solution was mixed with GST resin, and the supernatant was 
collected for the second step of the reaction. DHPS activity was measured in a 50 μL 
reaction containing 50 mM HEPES (pH 7.6), 10 mM Mg Cl2, 1% PEG 400, and 2% 
DMSO. For Kcat and Km determination, varying concentrations of DHPS, 0-3 μM 
14
C 
pABA, and 10 μM DHPPP from the first reaction were added to the reaction mixture. For 
Ki and IC50 determination, varying amounts of DHPS, 5 μM 
14
C pABA, 10 μM DHPPP 
and 0-50 μM of SMX were added to the reaction mixture. The reaction solution was 
incubated at 37
o 
C for 30 minutes. The labeled product of the enzymatic reaction was 
separated from the labeled pABA by thin layer chromatography. 25 μL aliquots of the 
reaction mixture were spotted onto PEI-cellulose coated plates and developed with 
ascending chromatography in 100 mM phosphate buffer, pH 7.4. With this method, we 
are able to perform Michealis-Menten kinetics for wild type and mutant enzyme activity 
as well as determine the IC50 values of candidate inhibitors. Since sulfonamides are 
competitive inhibitors of DHPS, Ki values were determined using the Cheng-Pursoff 
equation and represent the amount of inhibitor that will bind to half the enzyme active 
sites at equilibrium in the absence of substrate (Cheng & Prusoff, 1973). Enzyme kinetics 
data were determined by nonlinear regression using the Graphpad Prism4 software.  
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Chapter 7: Future Directions and Conclusions 
 
 
Developing a Robust Enzyme Assay 
 
 While our current assays are effective for interpreting changes in KM which occur 
as a result of sulfonamide-resistance mutations, the formation of sulfonamide products 
makes IC50 and Ki values difficult to interpret as DHPPP depletion may alter inhibition in 
a way that does not correlate physiologically. Therefore, a more robust method for 
studying sulfonamide inhibition is essential for understanding the mode of enzyme 
resistance. To overcome these issues, we propose the use of stopped-flow transient 
kinetics. 
 
Stopped-flow fluorescence spectroscopy is a useful tool for determining the 
dissociation constant (Kd) for individual substrates. This method is particularly useful in 
systems, such as the DHPS system, with intrinsically fluorescent substrates. Changes in 
the fluorescence of the pterin ring as well as pABA have been used to measure binding of 
substrates in both wild-type and sulfonamide resistant enzymes (Levy et al., 2008). We 
will use similar methods as described in Levi et al. to fully characterize the effects of 
sulfonamide resistance mutations on substrate and inhibitor binding. In addition, 
fluorescence probes can be used to understand conformational shifts which occur in loop 
regions of DHPS to facilitate substrate binding. Intrinsic Tryptophan fluorescence is 
responsible for the majority of fluorescence observed in proteins. A sequence analysis of 
the wild-type B. anthracis DHPS revealed only two Tryptophan residues which are far 
removed from the enzyme active site. Since neither residue is conserved, it stands to 
reason that they can easily be mutated out with no consequence to enzyme integrity. This 
frees the enzyme of unwanted fluorescence and allows the use of Tryptophan as a 
fluorescence probe. We will use site-directed mutagenesis to place Tryptophan residues 
in strategic regions of the enzyme to better understand the role of Loops-1 and -2 and 
their involvement in substrate binding.  
 
While it has been shown that pyrophosphate is essential for pABA binding (Levy 
et al., 2008), it has yet to be shown whether or not pyrophosphate is required for catalytic 
function. This is critical for understanding the catalytic mechanism as the presence or 
absence of pyrophosphate is directly linked to the nature of the transition-state 
intermediate. In the event of an SN1 reaction, pyrophosphate is released to form a 
carbocation intermediate prior to attack by pABA. However, pyrophosphate is required 
for the formation of the SN2 transition-state intermediate as proposed by Baca et al. and 
release of pyrophosphate in the absence of a nucleophilic attack can only occur as a result 
of an SN1 mechanism. Therefore, we will use inactive substrates which mimic pABA, 
such as benzoic acid, and monitor the release of pyrophosphate using our enzyme linked 
inorganic phosphate assay (ELIPA).  This approach will provide direct evidence as to the 
nature of the enzyme transition-state as well as a model for understanding the catalytic 
mechanism.  
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In the ELIPA, pyrophosphate released during the condensation of DHPPP and 
pABA is broken down into inorganic phosphate by a pyrophosphatase. The inorganic 
phosphate then reacts with 2-amino-6-mercapto-7-methylpurine riboside (MESG) to 
produce mercapto-methylpurine and ribose-1-phophate. Since the absorption ranges of 
MESG (330 nm) and mercato-methylpurine (360 nm) are different, the amount of 
pyrophosphate released can be measured by observing an increase in absorption at 360 
nm over time. 
 
In addition to our in vitro assays, we will use a DHPS knockout strain (JW3-144-
1; Baba et al., 2006) of E. coli to determine the minimal inhibitory concentration (MIC) 
of sulfonamides as a means of analyzing the effects of sulfonamide resistance mutations 
on bacterial growth.  Using the pBAD/His (Invitrogen) plasmid system, we will insert our 
DHPS gene of choice into the knockout cells. The pBAD/His system is advantageous 
because it provides a low copy system (pBR322 origin) with a leaky promotor (araC 
ORF) which will allow for approximate basal level expression of DHPS and DHPS 
mutant enzymes with no additional stimuli required. Two positive controls will be 
required for this experiment. First, transformation of the DHPS knockout strain with 
wild-type DHPS will provide a baseline for comparing MICs.  Second, a DHPS positive 
strain of E. coli will be used to determine wild-type MICs which may be altered in our 
plasmid system due to over expression of the plasmid inserts. A negative control will also 
be provided in which the DHPS knockout strain will be transformed with an empty 
plasmid. It should be noted that DHPS knockout strains of E. coli will require folate 
supplements. However, once the DHPS plasmid is transformed into the system 
supplements will be removed from the media and should not effect MIC determination. 
This is a widely used technique for understanding drug resistance (Rock et al., 2003; 
Zhang et al., 2004)) and will provide a more accurate method for evaluating the effects of 
drug resistance.  
 
 
Probing the Enzyme Mechanism 
 
 With the introduction of kits like Quickchange
®
 (Stratagene), site-directed 
mutagenesis has become a relatively straightforward method for designing point 
mutations. This technique will be of great importance for the advancement of this project 
as it will allow us to probe the enzyme active site for catalytically significant residues. 
Several residues have already been identified and will be mutated in ways as to both 
diminish and enhance catalytic activity according to predicted function. For instance, 
Asparagine 27 (B. anthracis) is predicted to coordinate the divalent cation which is 
predicted to protonate the pyrophosphate leaving group. Therefore, mutating Asparagine 
27 to an Alanine should diminish catalytic activity of the enzyme where as mutation to a 
Histidine should restore enzyme function.  
 
The current understanding of the DHPS mechanism assumes an SN2 transition 
state. However, conflicting data in the literature as to the direction of the nucleophilic 
attack requires further investigation into the nature of the enzyme transition-state. To 
distinguish between a SN2 and a SN1 mechanism, we have analyzed the enzyme active 
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site to identify conserved residues which aid in transition-state stabilization. In order for 
the reaction to proceed via SN1, the enzyme must have a way of stabilizing a carbocation 
intermediate. Aspartate 35 (B. anthracis) is a highly conserved residue on Loop-1 and is 
predicted to stabilize the formation of a carbocation by electrostatic interactions in the 
event of a SN1 reaction. In contrast, it is a less crucial candidate for an SN2 transition-
state because there is no longer a positive charge on the pterin moiety to be neutralized. 
Therefore, mutating Aspartate 35 to an Alanine or a lysine will provide critical 
information pertaining to the nature of the enzyme transition state.   
 
In addition, our preliminary data shows that Loop-2 folds into the active site upon 
substrate binding. Furthermore, disruption of the rigidity of Loop-2 by mutating of 
Proline 69 (B. anthracis) to a Serine diminishes catalytic activity by 3-fold. Evidence 
suggests that Loop-2 is necessary to direct Arginine 68 (B. anthracis) into the active site 
as mutation of Arginine 68 to an Alanine yields a 2-fold reduction in the rate of catalysis. 
To further understand the role of Loop-2, we will perform a series of mutations using an 
Alanine probe along Loop-2 as well as removal of Loop-2 to observe the effects on 
catalysis using our radiometric assay. In conjunction with our radiometric assay, we will 
determine effects of Loop-2 mutagenesis on pyrophosphate as well as pABA binding 
utilizing fluorescence techniques described by Levy et al.  
 
 
Fragment-Based Virtual Screening 
  
Structural data suggests that the pABA and pterin binding sites are separate, 
distinct regions in the DHPS molecule (Achari et al., 1997) allowing for the development 
of inhibitors capable of inhibiting sulfonamide-resistant forms of DHPS. Since the pterin 
binding pocket is highly conserved, it seems logical that it would be more difficult for the 
enzyme to accommodate mutations against pterin-based compounds. In addition, 
mutations that could potentially cause resistance to pterin-based inhibitors are likely to 
disrupt structural integrity since the pterin binding site is buried within the protein. In 
contrast, the pABA binding site involves flexible loop regions near the surface of the 
protein, and the rapid emergence of multiple sulfonamide resistance mutations clearly 
show that they are easily tolerated within the overall structure of the protein. By targeting 
the pterin binding site, we hypothesize that we will be able to overcome the problems of 
sulfonamide resistance which have arisen by mutations in the pABA binding site. 
 
While we have successfully identified several target compounds, the majority of 
these compounds have been pterin-like compounds which are often insoluble. To 
overcome this issue, we will use fragment-based virtual screening to identify scaffold 
compounds for lead optimization to produce highly efficient, drug-like inhibitors. The 
general approach to this aim will be structure-based drug design techniques in which 
virtual screening is used in synergism with structural and biochemical data.  
 
Fragment-based drug discovery is a highly integrated process which begins with 
the screening of fragment libraries and utilizes structural and biochemical techniques to 
produce drug-like compounds. We will adopt a modified rule of three in which library 
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searches are limited to compounds with a molecular weight less than 350 and no more 
that 5 rotatable bonds. Pharmacophore constraints will be applied based on substrate 
binding, but these will be limited to partial match derivatives to loosen the macro 
constraints and allow for ligand diversity. The hit compounds will be docked and scored 
using the methods described in preliminary data. Of the highest scoring compounds, the 
top 1% will be moved to biochemical studies. 
 
 We will use our radio-labeled assay as our primary method for studying 
inhibition. In contrast to the sulfonamides, these compounds will not be able to undergo 
enzyme catalysis, and we predict that this method will be an acceptable assay for 
inhibition kinetics. However, the ELIPA assay is available should an alternative be 
required. Compounds with greater than 30% inhibition of the wild-type DHPS will be 
moved into structural studies.  
 
 Visualization of these compounds is an essential step in our approach as it will 
allow us to see how the fragment compounds bind into the pterin pocket. This is 
advantageous for two reasons. First, it provides a model by which we can optimize these 
fragments into lead compounds with drug-like properties. Second, it provides a validation 
scheme for our docking and scoring functions. As a result of these studies, we will 
identify several lead compounds as candidates for novel therapeutics to be used against a 
wide variety of infectious agents.  
 
 Although we predict that the pterin pocket is less likely to accommodate 
resistance mutations, we cannot deny that this is a possibility. Therefore, we will grow E. 
coli cultures in agar containing varying amounts of drug concentration and observe for 
growth. The DHPS gene (folP) from the genomic DNA of cultures found to grow in the 
presence of drug will be PCR (polymerase chain reaction) amplified and sequenced to 
determine the presence of drug resistance mutations. In a similar fashion, E. coli cultures 
will also be used to determine the minimal inhibitory concentration (MIC) of these 
compounds to evaluate their ability to pass through the membrane barrier. Analysis of 
these compounds by these methods will allow us to evaluate and optimize chemical 
characteristics of the compounds before moving into an animal model and ensure the 
over all success of this project. 
  
 
Expanding the Pool of Known DHPS Structures 
 
With the assistance of the bioinformatics group at the Hartwell Center at St. Jude 
(Dr. Perdeep Mehta), we identified the DHPS gene from the genomic sequence of F. 
tularensis and discovered that it is fused with the gene for HPPK. Analysis of the 
sequence revealed that the C-terminal helix of DHPS, a key component of the TIM 
barrel, is missing. To ensure that the sequence is correct, we have obtained the genomic 
DNA and resequenced the DHPS region. Our initial sequence is correct and the gene has 
been PCR amplified and introduced into our standard pET28a expression vector, and 
pure soluble protein is now available for crystallization trials (Figure 6.1). However, 
biochemical data suggest that the DHPS component is inactive while the HPPK is active 
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(data not shown). Further analysis into the cause of inactivity is necessary and will be a 
priority in this project as it is likely to reveal crucial information regarding the enzyme 
mechanism. Y. pestis genomic DNA was obtained from Dr. Brubaker (Michigan State 
University), the gene was PCR amplified, expressed, and the purified protein is currently 
undergoing crystallization trials (Figure 6.1). The Y. pestis gene is a standard bacterial 
enzyme and is fully functional (data not shown). 
 
We will use crystallographic methods to incorporate other infectious agents into our 
inhibitor studies including those with already known structures (S. aureaus, M. 
tuberculosis, etc.) as well as class A agents of biowarfare, F. tularensis and Y. pestis. The 
structure determination of the F. tularensis and Y. pestis should be relatively 
straightforward. Preliminary crystals have been observed and are in the process of 
optimization. We anticipate that optimization of initial crystals will be successful. 
However, alternative methods are available should quality crystals prove difficult to 
obtain. 
 
The reductive methylation of surface lysines has been shown to alter the crystal 
formation of various proteins and is a straightforward and efficient way for improving 
crystal quality (Rypniewski et al., 1993; Rayment, 1997; Kobayashi et al., 1999; Walter 
et al., 2006). In hen egg white lysozyme, it was shown that the methylation of all six 
lysine residues resulted in only minor changes in the overall protein architecture 
(Rypniewski et al., 1993).  While several reductive methylation methods have been 
performed, we have chosen to employ formaldehyde as the alkylating reagent and 
dimethylamine borane complex as the reducing agent since they have been shown to have 
the mildest effects on the biochemical properties of the protein (Rayment, 1997).  
Examination of the B. anthracis DHPS structure revealed that the majority of lysines 
(8/20) present in the structure were surface residues. Based on sequence alignment, we 
predict this to be true of the Y. pestis (9 lysines) and F. tularensis (41 lysines) DHPS. 
 
Limited proteolysis as a second technique commonly used for obtaining quality 
crystals and is a straightforward technique. Using a variety of proteases, flexible regions 
of protein which may be involved in unfavorable interactions during crystallization can 
be identified and removed (Dong et al., 2007). Information obtained through treatment 
 
 
 
 
 
Figure 7.1: Purification Gels of Y. pestis and F. tularensis DHPS. Note that the F. 
tularensis DHPS has a larger molecular weight due to fusion with HPPK. 
Ft 
35 kDa Yp 
50 kDa Ft 
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with proteases can then be used to form new protein constructs for crystallization trials. 
This will be particularly useful with the F. tularensis construct as it may be necessary to 
cleave the HPPK and the DHPS enzymes to produce diffraction quality crystals.  
 
As mentioned above, the F. tularensis DHPS was found to be inactive. This is 
unexpected as the active site residues are present in the sequence and align well with the 
DHPS sequence of other organisms. One notable difference in the F. tularensis sequence 
is the loss of the c-terminal helix which is an essential component of the TIM barrel. We 
will use site-directed mutagenesis to reinstate this terminal helix and study the effects on 
activity using the ELIPA. In addition, microbiology techniques will be used to determine 
the effects of the F. tularensis DHPS in E. coli cells. This will yield one of two results. 
First, E. coli cells are able to grow using the F. tularensis DHPS indicating that the 
enzyme requires additional elements not present in our assay. Second, E. coli cells are 
unable to grow indicating that the enzyme is nonfunctional. In the latter scenario, it will 
be necessary to examine the genomic sequence of F. tularensis to determine the presence 
of divergent orthologs which may explain this unusual result. Furthermore, Larrson et al. 
has evaluated the genome sequence of F. tularensis and identified several holes in a 
variety of metabolic pathways indicating that the bacterium is becoming increasingly 
host-dependent. While they do not indicate any holes in the folate pathway based on 
sequence analysis, this may explain the inactive form of DHPS. Examination of why this 
enzyme is inactive remains an important aim for this project and will undoubtedly 
provide crucial evidence into the enzymatic mechanism.  
 
 
Conclusions 
 
 In an increasingly mobile and interconnected world, the transfer of infectious 
disease has become a serious threat through out the entire world and given rise to a need 
for novel therapeutics. The research proposed in this thesis gives a rational, valid method 
for overcoming the problems posed by present antibiotics and a plan for developing 
improved drug therapeutics.  
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